Sector
PharmaceuticalsOpen
₹385Prev. Close
₹371.25Turnover(Lac.)
₹222.46Day's High
₹385Day's Low
₹334.1552 Week's High
₹47052 Week's Low
₹175Book Value
₹135.16Face Value
₹10Mkt Cap (₹ Cr.)
569.96P/E
33.95EPS
10.93Divi. Yield
014 Aug 2023
12:00 AM
BookCloser
20 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
11 Aug 2023
12:00 AM
AGM
Announcement Date: 11 Aug, 2023
| Y/e 31 Mar( In .Cr) | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|
Equity Capital | 20.58 | 15.58 | 15.49 | 15.43 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 175.35 | 162.45 | 147.44 | 136.21 |
Net Worth | 195.93 | 178.03 | 162.93 | 151.64 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Revenue | 70.01 | 60.76 | 96.41 | 50.45 |
yoy growth (%) | 15.21 | -36.97 | 91.08 | 79.31 |
Raw materials | -39.06 | -35.75 | -52.98 | -25.9 |
As % of sales | 55.79 | 58.83 | 54.95 | 51.34 |
Employee costs | -5.21 | -5.65 | -5.22 | -4.21 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 7.5 | 5.22 | 19.52 | 7.15 |
Depreciation | -1.14 | -1.15 | -1.2 | -1.19 |
Tax paid | -1.35 | -0.76 | -4.75 | -0.96 |
Working capital | -1.1 | -5.99 | 6.43 | 6.49 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 15.21 | -36.97 | 91.08 | 79.31 |
Op profit growth | 276.91 | -91.66 | 197.85 | -2,095.55 |
EBIT growth | 39.14 | -70.16 | 178.12 | -1,655.73 |
Net profit growth | 38.1 | -69.81 | 138.33 | -17,121.7 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 154.37 | 139.6 | 114.23 | 68.52 | 53.32 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 154.37 | 139.6 | 114.23 | 68.52 | 53.32 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 4.48 | 2.92 | 2.91 | 2.67 | 4.13 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,587.35 | 124.83 | 3,80,990.4 | 867.6 | 0.85 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,534.8 | 76.42 | 1,20,383.36 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,490 | 32.38 | 1,20,295.96 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,154.55 | 33.79 | 1,16,159.65 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,770.9 | 26.36 | 1,12,931.2 | 1,034.8 | 0.59 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Mukund P Mehta
Whole-time Director
Bhavin M Mehta
Independent Director
Hemang Engineer
Whole-time Director
Mira Bhavin Mehta
Independent Director
Murti Vasudev Krishna
Independent Director
Venkita Subramanian Rajan
Company Sec. & Compli. Officer
Pushpa Nyoupane
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Kilitch Drugs (India) Ltd
Summary
Kilitch Drugs (India) Limited (KDIL) was incorporated in May, 1992 as a public limited company. The Company is a pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. The Company is one of the most reliable manufacturer of injectables in India and one of the largest manufacturer of cephalosporins in Africa having its manufacturing unit located in India and Ethiopia. Its services range from manufacturing to marketing a host of formulations in all dosage forms i.e. solid, liquid and parenteral forms of creating safe pharmaceutical solutions.The Company went public in Feb.94 to set up a pharmaceutical formulation plant at Thane to manufacture pharmaceutical products in the form of tablets, capsules,liquid orals, ointments, creams and injectables. Even before the plant was commissioned, the company came out with a rights issue in Oct.95 to expand the injectible capacity. Commercial production at the plant at Thane commenced in 1996. The company has two divisions - O T C and ethical.A Pharmaceutical formulation plant at Sanaa Republic of Yemen was set up at a cost of Rs 15 crore by entering into an agreement with Al-Fath Trading Corporation.It also entered into an agreement with a Miami company for the export of their medicine to West Indies, south and central America.The company entered into a contract with one of the leading company in the Republic of Yemen which it had set up at a cost of Rs 2.5-cr tanning unit, which was implem
Read More
What is the Kilitch Drugs (India) Ltd share price today?
The Kilitch Drugs (India) Ltd shares price on N/A is Rs.₹357 today.
What is the Market Cap of Kilitch Drugs (India) Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Kilitch Drugs (India) Ltd is ₹574.14 Cr. as of 23 Jul ‘24
What is the PE and PB ratio of Kilitch Drugs (India) Ltd?
The PE and PB ratios of Kilitch Drugs (India) Ltd is 33.95 and 2.68 as of 23 Jul ‘24
What is the 52 Week High and Low of Kilitch Drugs (India) Ltd?
The 52-week high/low is the highest and lowest price at which a Kilitch Drugs (India) Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Kilitch Drugs (India) Ltd is ₹175 and ₹469.85 as of 23 Jul ‘24
What is the CAGR of Kilitch Drugs (India) Ltd?
Kilitch Drugs (India) Ltd's CAGR for 5 Years at 25.94%, 3 Years at 25.69%, 1 Year at 102.23%, 6 Month at -2.89%, 3 Month at 4.62% and 1 Month at 15.63%.
What is the shareholding pattern of Kilitch Drugs (India) Ltd?
The shareholding pattern of Kilitch Drugs (India) Ltd is as follows:
Promoters - 69.23 %
Institutions - 0.00 %
Public - 30.77 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
